H. Eidam

发表

Hydroxyamide Analogs of Propofol Exhibit State-Dependent Block of Sodium Channels in Hippocampal Neurons: Implications for Anticonvulsant Activity

J. Kapur, H. White, Nicholas J. Hargus, 2007, Journal of Pharmacology and Experimental Therapeutics.

Discovery of GSK2193874: An Orally Active, Potent, and Selective Blocker of Transient Receptor Potential Vanilloid 4.

Carl A. Brooks, D. Holt, W. Bao, 2017, ACS medicinal chemistry letters.

Targeting IRAK4 for Degradation with PROTACs.

J. Harling, J. Emery, X. Lewell, 2019, ACS medicinal chemistry letters.

Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity

M. Gershon, B. Greenwood-Van Meerveld, M. Cheung, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Palladium- and copper-catalyzed 1,4-additions of organozinc compounds to conjugated aldehydes.

M. Herold, P. Eidam, J. A. Marshall, 2006, Organic letters.

Synthesis of 4‐Triisopropylsilyl‐3‐Butyn‐2‐ol by Asymmetric Transfer Hydrogenation

P. Eidam, J. A. Marshall, H. Eidam, 2007 .

TRPV4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury.

S. Matalon, S. Jordt, R. Willette, 2014, American journal of physiology. Lung cellular and molecular physiology.

TRPV 4 inhibition counteracts edema and inflammation and improves pulmonary function and oxygen saturation in chemically induced acute lung injury

S. Matalon, S. Jordt, R. Willette, 2014 .

Enteric RET inhibition attenuates gastrointestinal secretion and motility via cholinergic signaling in rat colonic mucosal preparations

R. Latorre, B. Greenwood-Van Meerveld, M. Cheung, 2018, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

An Orally Active TRPV4 Channel Blocker Prevents and Resolves Pulmonary Edema Induced by Heart Failure

H. Alsaid, W. Bao, R. Willette, 2012, Science Translational Medicine.

Discovery of GSK2798745: A Clinical Candidate for Inhibition of Transient Receptor Potential Vanilloid 4 (TRPV4).

Carl A. Brooks, D. Holt, D. Behm, 2019, ACS medicinal chemistry letters.

Optimization of a Novel Series of TRPV4 Antagonists with In Vivo Activity in a Model of Pulmonary Edema.

K. Thorneloe, M. Cheung, T. Roethke, 2013, ACS medicinal chemistry letters.

Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1.

R. A. Reid, D. Holt, R. Gampe, 2018, ACS medicinal chemistry letters.

(R)- and (S)-4-TIPS-3-butyn-2-ol. Useful precursors of chiral allenylzinc and indium reagents.

P. Eidam, H. Eidam, J. Marshall, 2006, The Journal of organic chemistry.